Fig. 8 | Cellular & Molecular Immunology

Fig. 8

From: The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation

Fig. 8

Graphical summary of the results. APG-2575 can synergize with ICIs through a mechanism involving the repolarization of TAMs from the M2 to the M1 phenotype, further enhancing CD8+ T-cell recruitment into the TME via the augmentation of CCL5 and CXCL10 secretion and thereby improving tumor immunosuppression

Back to article page